Search clinical trials for: Seasonal,quadrivalent,influenza vaccine

Total 1134 results

Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza, Vaccine

Germany
Tel-Aviv Sourasky Medical Center

Unknown

Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine

Rheumatoid Arthritis | Cellular Immune Response

Israel
Queen Saovabha Memorial Institute

Completed

Two-site Intradermal Influenza Vaccination in Elderly

Influenza

Thailand
Vanderbilt-Ingram Cancer Center

Active, not recruiting

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

Hematopoietic Cell Transplantation

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.

Influenza

Czechia
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States
Novartis Vaccines

Completed

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

Seasonal Influenza

Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

Interpandemic Influenza

Italy
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

Influenza

United States
Jiangsu Province Centers for Disease Control and...

Completed

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Influenza

China
International Centre for Diarrhoeal Disease Research...
Centers for Disease Control and Prevention; Institute of Epidemiology, Disease... and other collaborators

Recruiting

Cost-effectiveness of the Influenza Vaccination

Influenza Vaccine | Vaccination | Cost-Effectiveness

Bangladesh
St. Petersburg Research Institute of Vaccines and...

Recruiting

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

Vaccine Reaction | Influenza | Influenza, Human | Influenza Viral Infections

Russian Federation
Stanford University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

MELAS Syndrome

United States
National Centre for Epidemiology, Hungary
Netherlands Vaccine Institute; National Public Health Institute, Finland

Unknown

Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines (FLUSECUOEKH1)

Healthy Volunteers

Hungary
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

Influenza

Australia, Philippines
Shanghai Institute Of Biological Products
Shaanxi Provincial Center for Disease Control and Prevention

Recruiting

A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.

Influenza

China
Green Cross Corporation

Completed

Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)

Influenza

Korea, Republic of
Pfizer

Completed

Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

Respiratory Syncytial Virus

Australia
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Enrolling by invitation

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Influenza

China
University of Colorado, Denver
MedImmune LLC

Completed

Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults (QLAIV)

Human Immunodeficiency Virus (HIV)

United States
University of Pennsylvania
National Institute of Allergy and Infectious Diseases (NIAID); Stanford University and other collaborators

Recruiting

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

Influenza, Human

United States
Centers for Disease Control and Prevention, China

Completed

Persistence of Immune Response After Vaccination With Influenza Vaccine

Influenza, Human | Immunisation Reaction

China
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects

Influenza

Italy
Sanofi Pasteur, a Sanofi Company

Completed

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

Pregnancy | Influenza

United States
Novartis Vaccines

Completed

Immunogenicity and Safety of V70P5 Revaccination Subjects

Influenza

Finland
Green Cross Corporation

Completed

A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)

Influenza

Korea, Republic of
Sinovac Biotech Co., Ltd

Completed

Phase IV Clinical Trial of an Influenza Split Vaccine Anflu

Influenza
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

Influenza | Influenza Immunization

United States
PATH
Centers for Disease Control and Prevention; Institut de Recherche pour le Developpement

Completed

Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa

Influenza

Senegal
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects

Influenza

Germany
Centers for Disease Control and Prevention
Kenya Medical Research Institute; MCM Vaccines B.V.; Kenya Ministry of Health

Unknown

Seasonal Influenza Vaccine Effectiveness Study in Kenya

Influenza | Severe Acute Respiratory Illness | Influenza Like Illness

Kenya
Il-Yang Pharm. Co., Ltd.

Completed

Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'

Influenza
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
Green Cross Corporation

Unknown

A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study

Influenza

Korea, Republic of
Armed Forces Research Institute of Medical Sciences...

Completed

Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus

Influenza

Thailand
Pfizer

Completed

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

COVID-19 | Influenza, Human

United States
National Institute of Allergy and Infectious Diseases...

Completed

Age and Response to Flu Vaccines

Influenza | Influenza Immunisation

United States
Altimmune, Inc.
Optimal Health Research

Completed

Immune Response Following Seasonal Influenza Vaccination

Influenza

United States
Sinovac Biotech Co., Ltd

Completed

Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

Influenza and Pneumonia

China
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Response to Influenza Vaccine During Pregnancy (FLU-PG)

Influenza

United States
Johns Hopkins Bloomberg School of Public Health
Centers for Disease Control and Prevention

Completed

Immune and Hormone Response to Influenza Vaccine

Healthy

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

Seasonal Influenza

Italy
Pfizer

Recruiting

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

Influenza | Vaccines | Grippe

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam (GQM10)

Influenza

Vietnam
National Institute of Allergy and Infectious Diseases...

Completed

Development of Childhood Anti-Influenza Immunity

Influenza | Influenza Immunisation

United States
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age

Influenza

Canada, Honduras, Dominican Republic
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly

Influenza

Sweden
Sinovac Biotech Co., Ltd

Completed

Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants

Influenza

China

3

Subscribe